Cyprus Mail
Health

AstraZeneca Covid-19 antibody drug offers 83% protection over six months

file photo: a company logo is seen at the astrazeneca site in macclesfield
REUTERS/Phil Noble/File Photo

AstraZeneca on Thursday cemented its lead in bringing a preventative COVID-19 shot for the non-infected to market for people who do not respond well to vaccines, saying its antibody drug cocktail offered 83% protection over six months.

The injected therapy, called AZD7442 or Evusheld, had previously been shown to confer 77% protection against symptomatic illness after three months, in an earlier readout of the late-stage PROVENT trial in August.

The Anglo-Swedish company also said a separate study in patients with mild-to-moderate COVID-19 showed a higher dose of AZD7442 cut the risk of symptoms worsening by 88% when given within three days of first symptoms.

The latest results from longer-term follow-ups potentially position AstraZeneca, like rival Pfizer as a future supplier of both COVID-19 vaccines and treatments, with AstraZeneca having said the therapy’s “real advantage” was as a preventative shot.

“These new data add to the growing body of evidence supporting AZD7442’s potential to make a significant difference in the prevention and treatment of COVID-19,” Executive Vice President Mene Pangalos said in a statement.

Related Posts

Lockdown helped kids with asthma study shows

George Psyllides

New diabetes centre opens in Larnaca

Antigoni Pitta

The problems of hormone imbalance

CM Guest Columnist

By March 2022, Covid deaths in Europe could exceed 2.2 million – WHO

Reuters News Service

What you need to know about an Emergency Medical Alert System

CM Guest Columnist

Experimental chewing gum may reduce virus spread

Reuters News Service